Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H12O7S2.C4H10N2 |
Molecular Weight | 430.496 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CNCCN1.CC2=CC=C(C=C2)S(=O)(=O)OC3=CC=C(O)C(=C3)S(O)(=O)=O
InChI
InChIKey=HGAVKWUHBLHFNP-UHFFFAOYSA-N
InChI=1S/C13H12O7S2.C4H10N2/c1-9-2-5-11(6-3-9)22(18,19)20-10-4-7-12(14)13(8-10)21(15,16)17;1-2-6-4-3-5-1/h2-8,14H,1H3,(H,15,16,17);5-6H,1-4H2
Molecular Formula | C4H10N2 |
Molecular Weight | 86.1356 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C13H12O7S2 |
Molecular Weight | 344.36 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sultosilic acid is a benzenesulfonate ester. Sultosilic acid has been shown to be a hypolipidaemic drug both in animal experiments and in human clinical studies, chemically unrelated to other such drugs. The compound is being developed as a human drug (Mimedran ®) and is formulated as the piperazine salt (A-585). The recommended daily dose is three times one tablet containing 500 mg of Sultosilic acid.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3720792
three times one tablet containing 500 mg of Sultosilic acid
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:46:49 GMT 2023
by
admin
on
Fri Dec 15 15:46:49 GMT 2023
|
Record UNII |
69PPS56Y93
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
260-944-6
Created by
admin on Fri Dec 15 15:46:49 GMT 2023 , Edited by admin on Fri Dec 15 15:46:49 GMT 2023
|
PRIMARY | |||
|
DTXSID70973358
Created by
admin on Fri Dec 15 15:46:49 GMT 2023 , Edited by admin on Fri Dec 15 15:46:49 GMT 2023
|
PRIMARY | |||
|
100000087413
Created by
admin on Fri Dec 15 15:46:49 GMT 2023 , Edited by admin on Fri Dec 15 15:46:49 GMT 2023
|
PRIMARY | |||
|
162841
Created by
admin on Fri Dec 15 15:46:49 GMT 2023 , Edited by admin on Fri Dec 15 15:46:49 GMT 2023
|
PRIMARY | |||
|
69PPS56Y93
Created by
admin on Fri Dec 15 15:46:49 GMT 2023 , Edited by admin on Fri Dec 15 15:46:49 GMT 2023
|
PRIMARY | |||
|
57775-27-6
Created by
admin on Fri Dec 15 15:46:49 GMT 2023 , Edited by admin on Fri Dec 15 15:46:49 GMT 2023
|
PRIMARY | |||
|
m10394
Created by
admin on Fri Dec 15 15:46:49 GMT 2023 , Edited by admin on Fri Dec 15 15:46:49 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |